Novel protein may lead to extended intervals in AMD treatment

SAN DIEGO — Abicipar pegol, an engineered DARPin protein, shows promise for maintaining treatment gains at longer treatment intervals in patients with age-related macular degeneration, according to a speaker here. “DARPins are a novel class of single-domain fusion proteins that can be engineered to selectively bind any given target protein with high affinity and specificity,” Raj K. Maturi, MD, said at the American Society of Retina Specialists meeting. “Abicipar pegol is the first engineered DARPin with a high affinity to soluble forms of VEGF-A.”